DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. — Alliance for NanoHealth
Navigation
 
 
 
You are here: Home Research Publications Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Document Actions

C Lu, PH Thaker, YG Lin, W Spannuth, CN Landen, WM Merritt, NB Jennings, RR Langley, DM Gershenson, GD Yancopoulos, LM Ellis, RB Jaffe, RL Coleman, and AK Sood (2008)

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Am J Obstet Gynecol. 198(4):477.

OBJECTIVE: The purpose of this study was to examine the functional and therapeutic significance of pericytes in ovarian cancer vasculature. STUDY DESIGN: Tumor vessel morphologic condition and efficacy of endothelial and pericyte targeting were examined with the use of in vivo ovarian cancer models. The expression of platelet-derived growth factor (PDGF) ligands and receptors was examined in endothelial, pericyte-like, and ovarian cancer cells. RESULTS: Relative to normal vessels, tumor vasculature was characterized by loosely attached pericytes in reduced density. PDGF-BB was expressed predominantly by the endothelial and cancer cells, whereas PDGFRbeta was present in pericyte-like cells. PDGF-BB significantly increased the migration of and VEGF production by pericyte-like cells; PDGFRbeta blockade abrogated these effects. Dual VEGF (VEGF-Trap) and PDGF-B (PDGF-Trap) targeted therapy was more effective in inhibiting in vivo tumor growth than either agent alone. CONCLUSION: Aberrations in the tumor microenvironment contribute to endothelial cell survival. Strategies that target both endothelial cells and pericytes should be considered for clinical trials.